Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 문병인 | * |
dc.date.accessioned | 2016-08-28T12:08:34Z | - |
dc.date.available | 2016-08-28T12:08:34Z | - |
dc.date.issued | 2011 | * |
dc.identifier.issn | 1738-6756 | * |
dc.identifier.other | OAK-7517 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/221576 | - |
dc.description.abstract | Purpose: A 70-gene prognostic signature has prognostic value in patients with node-negative breast cancer in Europe. This diagnostic test known as "Mamma PrintTM (70-gene prognostic signature)" was recently validated and implementation was feasible. Therefore, we assessed the 70-gene prognostic signature in Korean patients with breast cancer. We compared the risk predicted by the 70-gene prognostic signature with commonly used clinicopathological guidelines among Korean patients with breast cancer. We also analyzed the 70-gene prognostic signature and clinicopathological feature of the patients in comparison with a previous validation study. Methods: Forty-eight eligible patients with breast cancer (clinical T1-2N0M0) were selected from four hospitals in Korea. Fresh tumor samples were analyzed with a customized micro array for the 70-gene prognostic signature. Concordance between the risk predicted by the 70-gene prognostic signature and risk predicted by commonly used clinico-pathological guidelines (St. Gallen guidelines, National Institutes of Health [NIH] guideline, and Adjuvant! Online) was evaluated. Results: Prognosis signatures were assessed in 36 patients. No significant differences were observed in the clinicopathological features of patients compared with previous studies. The 70-gene prognosis signature identified five (13.9%) patients with a low-risk prognosis signature and 31 (86.1%) patients with a high-risk prognosis signature. Clinical risk was concordant with the prognosis signature for 29 patients (80.6%) according to the St. Gallen guidelines; 30 patients (83.4%) according to the NIH guidelines; and 23 patients (63.8%) according to the Adjuvant! Online. Our results were different from previous validation studies in Europe with about a 40% low-risk prognosis and about a 60% high-risk prognosis. The high incidence in the high-risk group was consistent with data in Japan. Conclusion: The results of 70-gene prognostic signature of Korean patients with breast cancer were somewhat different from those identified in Europe. This difference should be studied as whether there is a gene disparity between Asians and Europeans. Further large-scale studies with a follow-up evaluation are required to assess whether the use of the 70-gene prognostic signature can predict the prognosis of Korean patients with breast cancer. © 2011 Korean Breast Cancer Society. | * |
dc.language | English | * |
dc.title | The 70-gene prognostic signature for korean breast cancer patients | * |
dc.type | Article | * |
dc.relation.issue | 1 | * |
dc.relation.volume | 14 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.index | KCI | * |
dc.relation.startpage | 33 | * |
dc.relation.lastpage | 38 | * |
dc.relation.journaltitle | Journal of Breast Cancer | * |
dc.identifier.doi | 10.4048/jbc.2011.14.1.33 | * |
dc.identifier.wosid | WOS:000289493500006 | * |
dc.identifier.scopusid | 2-s2.0-79955439208 | * |
dc.author.google | Na K.Y. | * |
dc.author.google | Kim K.S. | * |
dc.author.google | Lee J.E. | * |
dc.author.google | Kim H.J. | * |
dc.author.google | Yang J.-H. | * |
dc.author.google | Ahn S.-H. | * |
dc.author.google | Moon B.-I. | * |
dc.author.google | Kim R.M. | * |
dc.author.google | Ko S.M. | * |
dc.author.google | Jung Y.S. | * |
dc.contributor.scopusid | 문병인(7101878644;56119062300) | * |
dc.date.modifydate | 20231116123537 | * |